profit from every $100 of sales.
$0$100
Glaukos
$245.72-0.13% today
+167.6% in 1 year
1-year low $88.401-year high $247.16
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Glaukos sold, what it kept, and what it did with the cash.
Sales went from $283 million in 2022 to $507 million in 2025, with -$188 million of profit last year.
SalesProfit
Glaukos vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Glaukos | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Glaukos's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 225 | 294 | 283 | 315 | 383 | 507 | |
| 133 | 227 | 214 | 239 | 289 | 283 | |
| -124 | -33 | -102 | -124 | -108 | -200 | |
| -86 | -4 | -49 | -82 | -96 | -146 | |
| -120 | -50 | -99 | -135 | -146 | -188 | |
| -2.70 | -1.07 | -2.09 | -2.78 | -2.77 | -3.28 | |
| 59.2% | 77.3% | 75.6% | 76.0% | 75.5% | 55.7% | |
| -54.9% | -11.2% | -36.2% | -39.3% | -28.2% | -39.3% | |
| -53.5% | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,006 | 1,050 | 1,002 | 940 | 975 | 893 |
| Cash | 97 | 101 | 120 | 93 | 170 | 91 |
| Total debt | – | – | 382 | 384 | 103 | 104 |
| Total liabilities | 338 | 463 | 472 | 479 | 208 | 237 |
| 667 | 587 | 530 | 462 | 767 | 656 | |
| 44 | 46 | 47 | 48 | 53 | 57 | |
| -14.0% | -4.8% | -7.3% | -11.2% | -12.3% | -19.6% | |
| -18.0% | -8.4% | -18.7% | -29.2% | -19.1% | -28.6% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -23 | 25 | -33 | -58 | -61 | -15 | |
| 7 | 48 | 30 | 20 | 6 | 24 | |
| -30 | -23 | -63 | -78 | -68 | -39 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 46 | 30 | 39 | 44 | 50 | 63 |
Valuation
- –
- –
- –
- 12.5×
- 28.7×
- –
- –
- -0.3%
- -1.3%
- 0.0%
Profitability
- 55.7%
- -39.3%
- -37.0%
- -7.3%
- -10.4%
- -14.5%
- -26.5%
- -21.2%
- -10.7%
- 29.5%
Growth
- +17.7%
- –
- +20.1%
- –
- +5.4%
Financial health
- –
- 0.15
- 11.5%
- -18.7×
- 5.43
- 4.73
- 0.62
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 23%of 952
Bottom 8%of 883
Top 31%of 888
Bottom 37%of 987
What analysts expect
- Average price target
- $146.67
- Range
- $135.00 – $170.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | -0.18 | -0.30 | +40.0% |
| Feb 17, 2026 | -0.28 | -0.22 | −27.3% |
| Oct 29, 2025 | -0.16 | -0.27 | +40.7% |
| Jul 30, 2025 | -0.24 | -0.26 | +7.7% |
| Apr 30, 2025 | -0.22 | -0.33 | +33.3% |
| Feb 20, 2025 | -0.40 | -0.38 | −5.3% |
| Nov 4, 2024 | -0.28 | -0.52 | +46.2% |
| Jul 31, 2024 | -0.52 | -0.52 | +0.0% |
News
Could You Have Held Glaukos Stock Through Its Falls?Yahoo Finance · Nov 14, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
19No pass
Benjamin Graham
39No pass
Philip Fisher
34No pass
Peter Lynch
57No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
29No pass
Questions about Glaukos
Is Glaukos a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Glaukos AI analysis
What does Glaukos do?
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It is in Medical - Devices, based in Aliso Viejo, CA, United States, with 1,094 employees.
Does Glaukos pay a dividend?
No. Glaukos does not pay a dividend at the moment.
Is Glaukos stock halal?
Yes. Glaukos passes our halal screen: its business is permitted and its debt is 0.7% of its market value, under the 30% limit. How we check
How has Glaukos stock done over the past year?
Up 167.6% over the past twelve months, to $245.72. It traded between $88.40 and $247.16, close to its high.
Who are Glaukos's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Glaukos's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.